New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
about
Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infectionIdentification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virusA left-handed RNA double helix bound by the Z alpha domain of the RNA-editing enzyme ADAR1New Insights into the Biological Role of Mammalian ADARs; the RNA Editing ProteinsInnate immune responses in hepatitis C virus infectionDissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell lineModeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha InterferonHepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistenceFunctions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human DiseasesTo translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genesEnhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinaseRNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKRA-to-G hypermutation in the genome of lymphocytic choriomeningitis virusFunctions and regulation of RNA editing by ADAR deaminasesAdenosine deaminases acting on RNA (ADARs) are both antiviral and proviralPersistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell cultureRegulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DCRNA editing in the human ENCODE RNA-seq data.Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections.Inosine-containing RNA is a novel innate immune recognition element and reduces RSV infection.Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes.Intracellular innate immune cascades and interferon defenses that control hepatitis C virusTipping the balance: antagonism of PKR kinase and ADAR1 deaminase functions by virus gene products.Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelAdenosine deaminases acting on RNA, RNA editing, and interferon action.Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteinsSequestration and protection of double-stranded RNA by the betanodavirus b2 protein.MicroRNA editing facilitates immune elimination of HCMV infected cells.Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?ADAR proteins: double-stranded RNA and Z-DNA binding domains.Hepatitis C Virus. Strategies to Evade Antiviral ResponsesLRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in HepatocytesLandscape of post-transcriptional gene regulation during hepatitis C virus infectionADAR1 Facilitates HIV-1 Replication in Primary CD4+ T CellsdsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection.Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infectionIFP35 is involved in the antiviral function of interferon by association with the viral tas transactivator of bovine foamy virusLearning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.Guanylate-Binding Protein 1, an Interferon-Induced GTPase, Exerts an Antiviral Activity against Classical Swine Fever Virus Depending on Its GTPase Activity.Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA
P2860
Q24320104-95D7DAB8-EF21-43E2-AD74-375AC4C5B002Q24658111-C40F14CF-42E7-4C21-9BBF-3A8E8A2D7879Q24675816-D4C32896-0A31-4FEE-9686-2AF144D77207Q26782034-60969C49-DE38-4927-A260-B248156CD3F9Q27023055-54F2B7A9-B99E-41D4-A80E-4C54B73AB861Q27472675-064713CC-E264-4DC8-A78A-80DA0192BF55Q27488804-09C53C2C-729C-417E-91A0-E286C5DE24F8Q27488844-8D3A9747-9DDE-4A9C-8CD5-3ED44897B83CQ28078188-53303670-1F8B-4843-BF7E-5E9F8B551A0BQ28087690-A78F3DE5-2BB3-4C57-9B08-52402524EF8BQ28235509-09285065-1653-46B7-912E-684E425B0335Q28256487-2F330AE2-06A1-4B5F-AED1-30C9315B70DFQ28267000-8325E947-E87A-4164-BC42-4F9CD24A3DB5Q28274610-40B59B28-FC44-476E-9D05-FBD3668B9754Q28302608-04A50264-7D3E-4527-9174-5D616B752F31Q28473992-B561F08A-4D62-4FC9-AFE2-43D5BEF04B5BQ30414152-C6B5CEEC-4A5D-4D44-A3C7-5CC15A7B8AB9Q30562419-7CF9C1F0-9D6E-45DF-8754-2502710D68E5Q34046037-0B56DC40-B1FC-4F63-94D9-F3A14FD702E5Q34058607-09D11A76-E883-4C14-8AE3-BD32489E4856Q34163327-0F604ACD-53A1-41E2-A711-0D0D3766DEBCQ34208090-5E423F10-B3E4-4660-9444-095FB101AD76Q34208420-60465370-C2B5-4ECB-BD24-FD175B8CFDDAQ34334375-57EA6041-9DD1-4B21-B2C2-37357C6066F3Q34553883-8CACA4F5-4482-41CF-8FFF-C2C4EC256BD5Q34657013-39011474-8800-41B7-A8BA-8067328F1E5AQ34717783-13A20473-6D5B-469A-9079-02F23270E8B5Q35105657-B1B81CBD-AD03-4C61-B40A-5CC51FB17242Q35270150-4B9E3A53-155A-4F79-A6C7-6DFD2773B4E7Q35578834-BB45CBD2-F736-41ED-968D-023AC256233AQ35604054-AC609633-15DF-4DE5-88A3-8A3A45CEFFE7Q35671655-099A4ABA-2C33-4A1B-B547-E97F4857F45FQ35756038-4895FAB0-A5B3-432D-B0A7-60C1410630EAQ35858559-D32668F6-5A7D-4021-AC7C-3267F7548D34Q36432681-D8B57123-1CA5-4880-8A54-45E1F9FC44C7Q36460968-D4F61AE4-DB82-409F-A111-8040D8169980Q36540136-8F8BDF37-42FA-46E4-ABB9-BC383DF9236FQ36807121-AA067CE9-3DEE-4879-93DF-8E4FFA72A5CBQ36811907-E09577DC-6937-4F17-8108-B0CB4E189284Q36910780-F5DC2EC7-9D80-4832-97C9-7BC4D2F516A9
P2860
New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
New antiviral pathway that med ...... eron sensitivity through ADAR1
@ast
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en-gb
New antiviral pathway that med ...... eron sensitivity through ADAR1
@nl
type
label
New antiviral pathway that med ...... eron sensitivity through ADAR1
@ast
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en-gb
New antiviral pathway that med ...... eron sensitivity through ADAR1
@nl
altLabel
New Antiviral Pathway That Med ...... eron Sensitivity through ADAR1
@en
prefLabel
New antiviral pathway that med ...... eron sensitivity through ADAR1
@ast
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en-gb
New antiviral pathway that med ...... eron sensitivity through ADAR1
@nl
P2093
P2860
P921
P3181
P1433
P1476
New antiviral pathway that med ...... eron sensitivity through ADAR1
@en
P2093
Deborah R Taylor
Kathleen Mihalik
Miriam E R Darnell
Montserrat Puig
Stephen M Feinstone
P2860
P304
P3181
P356
10.1128/JVI.79.10.6291-6298.2005
P407
P577
2005-05-01T00:00:00Z